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All reagents were purchased from Sigma-Aldrich unless otherwise stated.  2-fluoroethyl-4-methylbenzene 
sulfonate was prepared using literature procedure. 1   1H NMR, proton-decoupled 13C NMR, and 19F NMR 
spectra were recorded on a Varian 400 MHz spectrometer; chemical shifts are reported in δ (ppm) with 
reference to either TMS or trichlorofluoromethane (CFCl3).  Mass spectra were obtained from the 
University of Missouri, Mass Spectrometry facility using nitrobenzyl alcohol (NBA) as matrix and analyzed 
via HRFab.  Purity of the 5 was assessed using an HPLC (Waters system 600 equipped with dual λ-detector 
2487 set to 254 and 280 nm) with a C-18 reversed-phase column (Phenomenex Luna®- C18; 100 Å; 5 µm; 
250 x 10 mm) using an eluent mixture of acetonitrile and water as a gradient system (75% acetonitrile in 
water over 20min) at a flow of 3 mL/min).  For characterization of 18F-9, HPLC flow detector was also 
interfaced with a radio-detector (BioScans) for analysis of radiolabeled chemical entities.   
Chemical Synthesis. 
5-methoxy-2-methylbenzo[d][1,3]selenazole (2). 
2 was obtained from N-(acetyl)benzoyl-2-iodoaniline using Woolins reagent under microwave conditions 
using established procedures. 2  
(Z)-4-(2-(5-methoxybenzo[d][1,3]selenazol-2-yl)vinyl)-N,N-dimethylaniline (3) 
To a mixture of 5-methoxy-2-methyl benzoselenazole (0.23 g, 1.0 mmol) and 6-dimethylamino pyrimidine 
carbaldehyde (0.15 g, 1.0 mmol) in DMSO was added 50 % KOH aqueous solution (10 mL). The resulting 
mixture was stirred at room temperature for 12 h.  After the completion of the reaction, the reaction 
mixture was filtered and the resulted solid was washed with water (3 × 5mL).  The wet solid was re-
dissolved in DCM (15 mL), washed with water (3 × 5 mL), and combined organic extract was dried over the 
sodium sulfate. The contents were filtered and concentrated under reduced pressure to obtain a yellow 
solid (2; 0.33 g; 94%; Rf = 0.60 , 3:2 hexane: EtOAc) and used for the next step without purification.  
 







1H NMR (400 MHz, CDCl3):  3.24 (s, 6H), 3.87 (s, 3H), 6.93 (d, J = 7.2 Hz, 1H), 7.16 (s, 2H), 7.50 (s, 1H), 7.70 
(d, J = 7.4 Hz, 1H), 8.52 (s, 2H); 13C NMR (100 MHz, CDCl3): 37.27, 55.52, 107.18, 114.85, 117.07, 121.54, 
124.81, 128.10, 132.81, 156.54, 159.16, 161.64, 172.49; HRMS (FAB) m/z calc. for C16H17N4OSe: [M+1]+ 
361.0567; found: 361.0572. 
 
(Z)-2-(4-(dimethylamino)styryl)benzo[d][1,3]selenazol-5-ol (4) 
The condensed product 3 (0.1 g, 0.3 mmol) was dissolved in dry DCM (5mL) under argon, cooled to -78 °C, 
stirred for 5 min, and treated with drop-wise addition of BBr3 (1M in DCM, 0.15 mL, 5.0 mmol). The 
resulting mixture was slowly brought to room temperature and stirred overnight. Following completion of 
the reaction (monitored by TLC), the reaction mixture was cooled to 0 °C and quenched with cold satd. 
sodium bicarbonate solution (5 mL). The reaction mixture was extracted with ethyl acetate (2 × 25 mL), 
combined extract was washed with water (2 × 10 mL), dried over anhydrous sodium sulfate, filtered, and 
the filtrates were evaporated under reduced pressure.  The residual red solid was purified by flash 






1H NMR (400 MHz, DMSO-d6):  3.17 (s, 6H), 6.83 (dd, J = 8.0, 1.6 Hz, 1H), 7.30 (s, 1H) 7.40 (d, J = 8.8 Hz, 
2H), 7.82 (d, J = 8.8 Hz, 1H), 8.75 (s, 2H), 9.63 (s, 1H); 13C NMR (100 MHz, DMSO-d6): 39.28, 109.72, 115.23, 
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117.66, 121.91, 125.92, 126.55, 133.49, 156.95, 157.07, 157.49, 161.59, 172.49; HRMS (FAB) m/z calc. for 
C15H15N4OSe: [M+1]+ 347.0411; found: 347.0412. 
 
(E)-5-(2-(6-(2-fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylpyridin-2-amine  (5) 
To a solution of alcohol derivative 4 (0.17 g, 0.5 mmol) in DMF (2mL) and 2-fluoroethyltosylate 1 (0.1g, 0.5 
mmol) dissolved in DMF (3mL) was added Cs2CO3 (0.24 g, 0.75 mmol). The contents were stirred at 130°C 
for 5h. Following completion of the reaction (monitored by TLC), the reaction mixture was quenched with 
ice-cold water and extracted with ethyl acetate (3 ×25 mL). The combined organic layer was washed with 
water (2 × 50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate evaporated under 
reduced pressure. The crude residue was purified by PTLC using hexane : EtOAc as an eluent mixture (60 : 






1H NMR (400 MHz, CDCl3): 3.24 (s, 6H), 4.28 (d, J = 27.6 Hz, 2H), 4.80 (d, J = 47.2 Hz, 2H), 6.97 (d, J = 7.2 Hz, 
1H), 7.17 (bs, 2H), 7.50 (s, 1H), 7.72 (d, J = 7.2 Hz, 1H), 8.52 (s, 2H); 13C NMR (100 MHz, CDCl3): 37.28, 67.31, 
67.51, 80.97, 82.67, 107.95, 115.36, 117.04, 121.46, 125.01, 128.78, 133.01, 156.57, 157.93, 158.57, 
161.66, 172.72; 19F NMR (282 MHz, CFCl3): -224 ppm; HRMS (FAB) m/z calc. for C17H18FN4OSe: [M]+ 
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To the solution of alcohol 3 (0.14 g, 0.4 mmol) and 2-(Bromoethoxy)-tert-butyldimethylsilane (0.096g, 0.4 
mmol) in DMF (5mL) was added Cs2CO3 (0.20 g, 0.6 mmol). The resulting mixture was stirred at 140 °C for 
6h. Following the completion of the reaction (monitored by TLC), it was quenched with the addition of ice 
cold water and extracted with ethyl acetate (3 X 25 mL). The organic layer was washed with water (2 X 50 
mL) and dried over anhydrous sodium sulfate and the solvent evaporated under reduced pressure to give 
crude product which were purified by PTLC using hexane : EtOAc (60 : 40) as eluent; Yield 61% (0.12 g); 






1H NMR (400 MHz, CDCl3): 0.12 (s, 6H), 0.92 (s, 9H), 3.24 (s, 6H), 4.01-4.03 (m, 2H), 4.09-4.12 (m, 2H), 6.94 
(dd, J = 8.8, 2.4 Hz, 1H), 7.17 (d, J = 1.2 Hz, 2H), 7.50 (d, J = 2.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 8.53 (s, 2H) ; 
13C NMR (100 MHz, CDCl3): 31.04, 42.24, 68.44, 76.22, 110.76, 112.22, 121.21, 124.34, 129.86, 140.02, 
142.74, 149.96, 152.44, 162.68, 172.86;  HRMS (FAB) m/z calc. for C23H33N4O2SiSe: [M]+ 505.1538; found: 
505.1527. 
(Z)-2-((2-(4-(dimethylamino)styryl)benzo[d][1,3]selenazol-5-yl)oxy)ethan-1-ol (7) 
To the solution of TBDMS protected compound (0.05 g, 0.1 mmol) in THF was added TBAF (1M in THF, 0.5 
mL, 0.5 mmol) and stirred at RT for 6h. Once the reaction is completed (monitored by TLC), the solvent is 
evaporated under reduced pressure to give crude product which was purified by PTLC using EtOAC: Hex 












 1H NMR (400 MHz, CDCl3): 3.24 (s, 6H), 3.99-4.01 (m, 2H), 4.14-4.16 (m, 2H), 6.68 (d, J = 12.0, Hz, 1H), 6.75 
(d, J = 12.0, Hz, 1H), 6.94 (dd, J = 8.8, 2.4 Hz, 1H), 7.56 (d, J = 2.8 Hz, 1H), 7.65 (d, J = 9.2 Hz, 1H), 8.65 (s, 2H) 
13C NMR (100 MHz, CDCl3 ): 37.24, 61.35, 69.61, 108.29, 115.57, 117.06, 121.49, 124.94, 125.45, 130.94, 
132.99, 155.85, 156.57, 158.05, 158.55, 169.12, 172.72; HRMS (FAB) m/z calc. for C17H19N4O2Se: [M]+ 




Pyridine (0.08 g, 1 mmol) and DMAP (0.0012 g, 0.01 mmol) were added to a solution of alcohol 6 (0.08g, 
0.2 mmol) in DCM (10 mL) at 0°C. Thereafter, p-toluene-sulfonylchloride (0.076 g, 0.4 mmol) dissolved in 
DCM (2 mL) was added and the resulting solution was stirred at room temperature for 7 h, and quenched 
by the addition of water (15 mL). The resulting mixture was extracted with DCM (3 X 5 mL), organic 
extracts were combined, dried over Na2SO4, filtered, and concentrated. Finally, the residue was purified by 
Prep TLC using the eluent mixture (Hex/EtOAc = 60 : 40) to obtain the compound as a Dark yellow solid. 
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1H NMR (400 MHz, CDCl3): 2.43 (s, 3H), 3.24 (s, 6H), 4.20 (bs, 2H), 4.41 (bs, 2H), 6.71 (d, J = 9.0 Hz, 1H), 6.81 
(d, J = 9.0 Hz, 1H), 7.17-7.41 (m, 4H), 7.65-7.69 (m, 1H),  7.82 (d, J = 7.6 Hz, 2H),8.52 (s, 1H), 8.66 (s, 1H) ; 
13C NMR (100 MHz, CDCl3): 21.64, 37.23, 65.72, 68.06, 108.04, 108.25, 115.08, 115.50, 116.88, 121.41, 
124.78, 124.96, 125.25, 128.00, 129.85, 131.04, 133.12, 144.95, 156.60, 157.35, 158.59, 162.68, 171.84; ; 
HRMS (FAB) m/z calc. for C24H24FN4O4SNaSe: [M]+ + Na 567.0581; found: 567.0580. 
 
(E)-5-(2-(6-(2-fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylpyridin-2-amine  (5) 
Dry tetrabutylammonium fluoride (0.065g, 0.25 mmol) was dissolved in dry acetonitrile (5 mL) under argon 
and treated with the acetonitrile solution of tosylated precursor 8 (0.054g, 0.1 mmol) and refluxed at 110 
°C. The progress of the reaction was monitored via the TLC. Following completion of the reaction, the 
solvent was evaporated and the residue was extracted with EtOAc (2 X 10 mL). Combined organic extracts 
were dried with Na2SO4, filtered, evaporated, and the residue was purified using thinlayer chromatography 
employing a mobile eluent mixture (Hex : EtOAC = 60:40) to obtain 4 (0.028 g; 71% ; bright yellow solid; Rf 
= 0.41; 3:2, EtOAc-hexane). 
 
X-ray Crystallography.  
X-ray quality Crystals of 5 were obtained by slow diffusion of MeOH to a DCM solution of 5 containing 1% 
ACN.  A crystal of approximate dimensions 0.594 x 0.076 x 0.054 mm3 was mounted on a MiTeGen 
cryoloop in a random orientation. Preliminary examination and data collection were performed using a 
Bruker X8 Kappa Apex II Charge Coupled Device (CCD) Detector system single crystal X-Ray diffractometer, 
equipped with an Oxford Cryostream LT device. Data were collected using graphite monochromated Mo K
 radiation (= 0.71073 Å) from a fine focus sealed tube X-Ray source.  Preliminary unit cell constants were 
determined with a set of 36 narrow frame scans. Typical data sets consist of combinations of   and  scan 
frames with typical scan width of 0.5 and counting time of 15 seconds/frame at a crystal to detector 
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distance of 4.0 cm. The collected frames were integrated using an orientation matrix determined from the 
narrow frame scans. Apex II and SAINT software packages 3 were used for data collection and data 
integration. Analysis of the integrated data did not show any decay. Final cell constants were determined 
by global refinement of   reflections harvested from the complete data set. Collected data were corrected 
for systematic errors using SADABS and TWINABS 3 based on the Laue symmetry using equivalent 
reflections. 
  Crystal data and intensity data collection parameters are listed in Table 1. 
Structure solution and refinement were carried out using the SHELXTL- PLUS software package. 4  The 
structure was solved by direct methods and refined successfully in the space groups, P21/n.  Twin 
refinement was carried out for a two component twin. Full matrix least-squares refinements were carried 
out by minimizing w(Fo
2-Fc
2)2. The non-hydrogen atoms were refined anisotropically to convergence. All 
hydrogen atoms were treated using appropriate riding model (AFIX m3).  The final residual values (R1= 
0.063, wR2= 0.171) and structure refinement parameters are listed in Table 1.   Furthermore, a molecule of 
CH3CN was also located in the lattice and refined with partial occupancies and geometrical restraints.   The 
crystal structure of 5 revealed a planar geometry with fluoride atom displaced from the mean plane and 
presence of both inter- and intra-molecular hydrogen bonding (SI-Figure 1).  Complete listings of structural 
refinement parameters, atomic coordinates and equivalent  isotropic displacement parameters, 
interatomic distances and bond angles, anisotropic displacement coefficients for the non-hydrogen atoms, 
hydrogen coordinates and isotropic  displacement parameters, and torsion angles for 5 are listed (Tables 1-










Preparation of Aβ fibrils. 
Commercially available amyloid peptide Aβ1-42 (433 µg) was gently dissolved in PBS (1 mL, pH 7.4, 100 
µM)5.  The solution was incubated for 36-48 h at 37°C with continuous gentle shaking to avoid gel 
formation at the meniscus.  The aggregated peptide suspension was stored at -80°C until needed (the 
suspension did not show any noticeable change in properties for at least 8 weeks). 5   
 
Binding of 5 with Aβ fibrils 
In vitro binding assays to preformed fibrils were performed using literature procedures. 5,6  Prior to 
binding assays, the Aβ fibril stock solution was thawed, diluted with PBS to the final concentration of Aβ 
fibrils (1µM), and incubated with increasing concentrations of the fluorescent molecule 5 for 30 min. 
Following excitation at 410nm, fluorescence spectrum of 5recorded in PBS containing 5% ethanol showed a 
broad emission peak 450-540nm with Emax at 503nm.  Upon incubation with preformed of Aβ1-42 aggregates, 
the peak at 503nm shifted slightly (Emax 485 nm) and showed remarkable enhancement in fluorescence, 
indicating binding to Aβ aggregates, similar to enhancement in fluorescence of thioflavin-T in PBS (a positive 
control; data not shown).  Additionally, it is also noteworthy that no fluorescence was observed using Aβ 
aggregates alone in PBS upon excitation at 410 nm (a negative control).  All measurements were made in 
triplicates; fluorescence of either 5 alone or fibrils at a given concentration was subtracted.  The data were 
fit to a single site model using GraphPad Prism, version 4.03 (GraphPad Software, San Diego, California, USA) 
to obtain the binding constant 1.58±.05nM (SI-Figure 2). 
 
Histochemical Staining of Mouse Brain Tissues  
Mice, 24 month old APP+/-/PS1+/- and age-matched control BL/6 (WT), were sacrificed and their brains 
removed, fixed in 4% formaldehyde, and stored in 30% sucrose for 3 days.  Serial brain tissue sections (50 
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µm) were cut in the coronal plane on a freezing sliding microtome and stored at -20°C. 7,8  Tissue was 
stained as free-floating sections.  Prior to staining, tissue sections were permeabilized with PBS-Tritron-X-
100 (0.25%) for 30 minutes, and then blocked with 1% non-fat dry milk in PBS-Ttiton-X-100 for 60 minutes. 
Hippocampus tissue sections of APP+/-/PS1+/- and age-matched control BL/6 (WT, SI Figure 3) were 
incubated with fluorescent molecule 5 (100 nM dissolved in 1% ethanol in PBS) for 60 minutes, and washed 
3-times with PBS-Triton-X-100.9  Thereafter, tissue sections were incubated with mouse-anti-Aβ (mHJ3.4) 7 
that was directly conjugated to Alexa 568 for 90 minutes and washed 3-times with PBS-Triton-X-100.  
Tissue sections were mounted onto SuperFrost Plus slides, dried overnight at room temperature, and then 
sealed with Fluoromount G (Southern Biotech, Birmingham, AL). Finally, stained sections were imaged 
using Chroma Filter sets (5: FITC Ex 425nm, Em 540nm; anti-Aβ (mHJ3.4) antibody-Alex568: Ex. 560 ± 
25nm, Em. 645 ± 35nm) using a Nikon Eclipse E800 epifluorescence microscope. 
 
Histological Staining of Human Brain Tissue  
Postmortem brain tissues from autopsy-confirmed AD patients and their approximate age-
matched healthy controls were obtained through the Knight Alzheimer’s Disease Research Center 
(ADRC) Washington University School of Medicine and processed according to a protocol 
approved by institutional ADRC executive committees10.    All methods were carried out on human 
tissues in "accordance" with the approved guidelines.  Formalin-fixed, paraffin embedded tissue 
sections were obtained from AD brains and age-matched neurological and neuropathological 
controls.  Brain tissue samples were either fixed in 4% formaldehyde, and stored in 30% sucrose 
for 3 days and sliced (10 µm) a freezing sliding microtome; or tissue was fixed in 10% neutral 
buffered formal saline, embedded in paraffin wax, and cut at 10 µm.  Tissue sections were 
incubated with either a fluorescent molecule 5 (10 µM) or treated with anti-Aβ (10D5, dilution: 
1:10,000; Eli Lilly, Indianapolis, IN) or thioflavin-S or specific antibodies for biomarker proteins of 
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other neurodegenerative diseases (SI, Figure 4A & 4B).  Sections were visualized, processed, and 
analyzed using a Pascal confocal microscope. 
Preparation of Human Brain Homogenates. 
Well-established literature procedures were used for preparation of AD homogenates. 11,12 Grey matter 
was isolated from frozen postmortem frontal cortex tissue by dissection with a scalpel. To prepare 
insoluble fractions, dissected tissue was sequentially homogenized in four buffers (3 ml/g wet weight of 
tissue) with glass Dounce tissue grinders (Kimble): 1) High salt (HS) buffer: 50 mM Tris-HCl pH 7.5, 750 mM 
NaCl, 5 mM EDTA; 2) HS buffer with 1% Triton X-100; 3) HS buffer with 1% Triton X-100 and 1 M sucrose; 
and 4)50 mM Tris-HCl, pH 7.4. Homogenates were centrifuged at 100,000×g after each homogenization 
step, the pellet was resuspended, and homogenized in the next buffer in the sequence.  
 
Radiochemical Synthesis 18F-9. 
 
For radiolabeling, tosylated precursor ( 7, 3mg) dissolved in dry acetonitrile (400 µL) was transferred into 
an amber colored vial containing anhydrous kryptofix 2, 2, 2 (Sigma Chemicals)/K2CO3/18F-fluoride, 
obtained using standard procedures. The reaction mixture was heated to 100°C for 20 min in an oil bath, 
cooled in ice-cold water, and diluted to 5% acetonitrile in water.  The crude mixture was loaded on a C-18 
sepPak cartridge (Waters), primed with ethanol (5mL) and water (10mL).  The C-18 sep-Pak was washed 
with water (5mL × 6), 25% acetonitrile (5mL × 4), and finally eluted with 100% acetonitrile (1 mL).  The 
crude mixture was purified on purified using high-performance liquid chromatography (dual λ detection set 
at 254 and 280 nm) equipped with a radiodetector (Bioscans) using a C-18 column (Phenomenex; 5-µm 
250×10 mm) using an eluent gradient acetonitrile 75%-95% over 20 min (flow rate: 3 mL/min).  The 
fraction of 18F-9 eluting at 11 min (radiochemical purity > 95%; radiochemical yield:  30%; specific activity: 
1500-1700 Ci/mmol (Si Figure 5); was collected, concentrated, resuspended in ethanol/saline, and 
employed for bioassays.  





Binding assays were performed using previously described methods.11 Briefly, a fixed concentration (0.25 
µM/well) of Aβ1–42 fibrils was incubated for 1 h at 37 °C with increasing concentrations of [18F]-9 (0.1 nM-15 
nM) in 30 mM Tris-HCl pH 7.4, 0.1% BSA in a reaction volume of 150 µl. A fixed ratio of hot:cold ([18F]-9  
and 5) was used for all radioligand concentrations. The exact hot:cold ([18F]-9 : 5) ratio was measured in 
each experiment by counting an aliquot of a sample (2 µl) of the radioligand preparation in a scintillation 
counter. Binding of [18F]-9  to human brain homogenates was assessed by incubating samples of insoluble 
fraction (1.25 µg insoluble protein/well) from AD subjects, with increasing concentrations of [18F]-9  
(0.1nM-18 nM) for 1 h at 37 °C.  Nonspecific binding was determined in parallel experiments in the 
presence of 5 (1 µM) as a competitor. Bound and free radioligand were separated by vacuum filtration 
through glass fiber 96-well filter plates (Millipore Multiscreen HTS FB filter plate, Cat# MSFBN6B50), 
followed by washes using ice cold assay buffer (3×150 µl). Glass fiber filters containing the bound ligand 
were mixed with Optiphase Supermix scintillation cocktail (150µl; PerkinElmer) and counted immediately.  
All data were obtained in triplicate and analyzed by curve fitting to a one-site binding model using 
nonlinear regression employing Graphpad Prism software (version 4.0) to determine Kd and Bmax values. 
Bmax values were calculated in pmol/gram wet weight of brain tissue. 13  
 
Human Serum Stability Analysis. 
Human serum (Sigma Aldrich) was thawed.  Serum (100µL) was taken, diluted with saline to 10%,  and 
incubated with HPLC purified fraction of 18F-9 (100µCi each) at 37 °C for 30 min, 1h and 3h, respectively.  




Scientific Reports                                                                                                                      Version of August 4, 2016 
SI-13 
 
Autoradiography of Human Brain Sections and Immunohistochemistry Correlation 
Autoradiography and immunohistochemistry (IHC) were performed as previously described14 with minor 
modifications. Briefly, a sample of frozen AD frontal cortex was sectioned using a TBS Minotome PLUS 
Cryostat set at a thickness of 12 microns. The tissue sections were thaw-mounted onto Superfrost Plus 
(Fisherbrand 12-550-15) microscope slides and allowed to air dry for 10–15 min prior to storage at -80 °C. 
Adjacent sections were incubated in either 2 nM 18F- 9 or 2 nM 18F- 9 plus 1 µM cold 5 (20 ml/slide) for 60 
min at room temperature. Sections were then washed at RT in 30 mM Tris-HCl pH 7.4 for 1 min, 70% 
ethanol/30 mM Tris-HCl for 2 min, 30% ethanol/30 mM Tris-HCl for 1 min and 30 mM Tris-HCl for 1 min. 
The sections were then dried and exposed to a phosphor imaging screen (BAS-TR 2025) for 45 min. 
Autoradiography images were obtained on GE Typhoon System FLA-9500 (Tokyo, Japan) at 25 µm 
resolution. Data was exported as linear 16-bit grayscale TIFF images and further processed by Adobe 
Photoshop CS3. For IHC, the same sections were blocked for 60 min at room temperature with 3% milk-
0.25% Tween20-PBS buffer. After a 1 min wash in 0.5% milk-PBS-0.25% Tween 20, the sections were 
stained with monoclonal anti-Aβ antibody HJ 3.4 (1.7 μg/ml in 0.5% milk-PBS-0.25% Tween 20) at 4 °C 
overnight. The slides were washed 3 x 5 min with PBS-0.25% Tween 20, then dried and cover-slipped with 
DAPI Fluoromount-G (Cat# 0100-20, SouthernBiotech, Birmingham, AL). IHC images were obtained on a 
NanoZoomer 2.0-HT System (Olympus) at 20x resolution with DAPI and TRITC fluorescence filters using 
NDP.scan 2.5 software (Olympus).  
 Ex Vivo Autoradiography of Mice Brain Sections and Immunohistochemistry Correlation 
Ex-vivo autoradiography was performed by tail vein injection of [18F]-9 (170 µCi, 8% ethanol in saline) in a 
24-month old APP/PS1 transgenic (Tg) mouse and an age matched WT BL6 control female mouse.  
The transgenic and WT mice were sacrificed at 30 min post injection. Brain tissue was removed and 
immediately frozen on powdered dry ice. Coronal sections (20 µm) were cut on a cryotstat (Leica), 
mounted on Superfrost Plus (Fisherbrand 12-550-15) microscope slides and allowed to air dry. The slides 
Scientific Reports                                                                                                                      Version of August 4, 2016 
SI-14 
 
were then exposed to a phosphor imaging screen (BAS-SR 2025) for 2 h before scanning on a Typhoon FLA-
9500 system. The same sections were then immunostained with anti-Aβ antibody HJ 3.4 as described 
above. Autoradiography images were analyzed using MultiGauge software (Fuji, Tokyo, Japan). To quantify 
radiotracer accumulation, three target regions of interest (ROIs) (two in cortex and one in amygdala) were 
selected in Tg and WT sections where Aβ plaque density was high in Tg. Hypothalamus was selected as a 
reference ROI with low plaque density (The Mouse Brain in Stereotaxic Coordinates, 2nd edition).   
The count intensity (expressed as quantitative light unit (QL)/pixel2) was measured for each ROI after 
background subtraction, and target/reference ratios for Tg and WT brain were used to compare 




All animal procedures were approved by the Washington University Animal Studies Committee (Protocol # 
20150147; Expiration 7/31/18).  Thus, biodistribution studies were carried out in "accordance" with the 
approved guidelines.  Pharmacokinetics of 18F-9 in brain and other critical tissues of normal male 12 week 
old BL6 (WT; 28-36 g) mice were determined as previously described 15. Briefly, 18F-9 (740 kBq) was 
dissolved in 100 μl saline containing 10% ethanol.  All animals were anesthetized by isoflurane inhalation 
and injected with radiotracer 18F-9 (740 kBq, 100 μL) via bolus injection through a tail vein. Animals were 
sacrificed by cervical dislocation under anesthesia at 5, 30, 60, and 120 min after injection (n = 3 each). 
Blood samples were obtained by cardiac puncture, organs then harvested rapidly, and all tissue samples 
analyzed for -activity. Data (SI-Table 1) are expressed as the percentage injected dose (%ID) per gram of 
tissue (tissue kBq (injected kBq)-1 (g tissue)-1 x 100). 
 
Multiphoton Imaging 
 All experimental protocols were approved by the Animal Studies Committee at Washington University 
(protocol #20140182).   Thus, multiphoton imaging studies were carried out in "accordance" with the 
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approved guidelines. 15-month-old APP+/-/PS1+/- mice were imaged using intravital multiphoton 
microscopy to assess pharmacokinetic profiles of the 5.  The thinned-skull cranial windows were prepared 
on the day prior to imaging, as previously described16-18.   Briefly, mice were anesthetized under volatile 
isoflurane (2% induction, 1.5% maintenance), the scalp and periosteum were removed to expose the skull.  
A speed drill and microsurgical blade (Surgistar) were used to thin the skull until the skull window (1.5 mM 
in diameter) was transparent and displayed flexibility (approximately 10-20 µm thick). Animals were 
mounted on a custom-built stereotaxic apparatus and a small ring of molten bone wax was applied to the 
skull surrounding the perimeter of the window to create a water immersion chamber. The cranial window 
was centered under the objective lens on a two-photon microscope [LSM 510 META NLO system (Carl Zeiss 
Inc.) with a Cameleon Ti:Sapphire laser (Coherent Inc.)]. Prior to imaging, mice were intravenously injected 
with dextran-Texas Red conjugate to mark blood vessels (33mg/kg dissolved in PBS). 
For imaging 5 labeled plaques, two-photon fluorescence was generated with 800 nm excitation, 
and fluorescent emission was detected in the range of 435-485nm. To image dextran-texas red labeled 
vessel, 800 nm was used for excitation, and 565-615nm for emission.  A 10× water-immersion objective 
[numerical aperture (NA) = 0.33, Zeiss) was used.  Time-lapse multiphoton imaging was initiated 5min 
before dye 5 (2 mg/kg dissolved in 20% DMSO in 80% propylene glycol) was injected.  Dye 5 was 
intravenously injected over a 3-min infusion period (19). Three-dimensional volumes were acquired (by 
collecting a stack of x-y sections starting at the surface of the thinned skull to 100 microns deep into the 




All microPET/CT imaging studies were approved by the Washington University Animal Studies Committee 
(Protocol # 20150147; Expiration 7/31/18) and conducted in "accordance" with the approved guidelines.  
For imaging, female double transgenic mouse (BL6/APP/PS1, 18 months old, n =3) and a female wild-type 
mouse (BL6; 18 months old, n=3) were anesthetized with isoflurane (1.5 -2.5 %) in oxygen at flow rate of 1-
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2 L/min via an induction chamber and maintained with a nose cone. Following anesthesia, the mice were 
secured with their heads in the center of the field of view, fixed in the scanner in prone head first position 
(HFP), and placed in an acrylic imaging tray.  Micro-PET imaging was performed using Inveon PET/CT 
scanner (Siemens Medical Solutions) following intravenous tail-vein injection of HPLC-purified 18F-9 (5.032 
MBq; 28 µl;  35% ethanol in saline) employing the catheter system in a slow bolus, followed by flushing 
with isotonic saline solution.  PET dynamic data acquisition was performed over 1h starting immediately 
following injection of the tracer. The emission data were normalized, corrected for attenuation, scatter, 
and decay. Attenuation correction was obtained using the co-registered CT data. The image volume 
consisted of 256×256×159 voxels, with a size of 0.39×0.39×0.8 mm3 per voxel for the Inveon scanner. For 
anatomical visualization, PET images were co-registered with CT images from an Inveon PET/CT scanner. 
For analysis, brain uptake (Bq/mL) was normalized to injected dose and weight of animals.   ROIs were 
drawn within the brain excluding cerebellum, counts were normalized to %ID/g, and weight of the mice to 
generate SUV values. PET data were also analyzed using ReferenceLogan plots to obtain distribution 
volume ratios (DVR) for APP/PS1 and WT mice brains, using cerebellum as a reference region.   All image 












SI Figure 1. View of crystal packing of 5 with inter- and intramolecular H-bonding network. 
 
 






SI Figure 2.   5 (Fluselenamyl) was incubated in increasing concentrations with a fixed final concentration 
of Aβ1-42 aggregates (100nM) at 37°C for 30 min in PBS. All measurements were made in triplicates; 
fluorescence of either 5 alone or fibrils at a given concentration was subtracted.  The data were fitted into 
a single site model using GraphPad Prism, version 4.03 (GraphPad Software, San Diego,Ca, USA) and 
binding constant was found to be 1.58±0.05nM. 
  






                  5 (Fluselenamyl)        Anti-Aβ Antibody mHJ3.4-AF568              Merged 
 
 
SI Figure 3.  Staining of brain hippocampus sections of Bl6 (control) 10 months old mice, using either 5 or 
immunostained with HJ3.4 mouse monoclonal antibody and visualized by donkey-antimouse Alexa 568 
(positive control). The slides were analyzed on a Zeiss LSM 5 PASCAL confocal system coupled to a Zeiss 










SI Figure 4A. In the Alzheimer’s disease (AD) brain β-amyloid deposits are present as diffuse plaques 
(Arrow), more compact plaques (Arrowhead), and in the walls of some blood vessels (cerebral amyloid 
angiopathy, Asterisk) (beta-amyloid (10D5) immunohistochemistry). B: Fluselenamyl (5) detects compact 
plaques (Arrowhead), a proportion of diffuse plaques (Arrow), and vascular deposits (Asterisk). C: 
Thioflavin S detects compact fibrillar beta-amyloid plaques and vascular amyloid. AI-187 does not detect 
any changes in the normal aging brain (D), or in the inclusions of other neurodegenerative diseases: E, 
Parkinson’s disease (midbrain); F, multiple system atrophy (cerebellum); G, Huntington’s disease (caudate 
nucleus); H, progressive supranuclear palsy (caudate nucleus);  I, corticobasal degeneration; J, 
frontotemporal lobar degeneration with TDP-43 proteinopathy; and K, amyotrophic lateral sclerosis with 
TDP-43 proteinopathy. A to D, F to J, Magnification: 10X; E and K, Magnification: 20X.  
 









Disease Brain Area Block# Fluselenamyl (5) Positive 
Control 
(antibody) 
Alzheimer’s disease + CAA Frontal Lobe L1 Positive (diffuse and compact Aβ Plaques) 
                                 + CAA 
10D5 
Normal control Frontal Lobe L1 Negative 10D5 
Parkinson’s disease Medulla L12 Negative pSYN 
Multiple system atrophy Cerebellum L14 Negative pSYN 
Huntington’s disease Striatum L6 Negative 1C2 
Progressive supranuclear palsy Striatum L6 Negative PHF1 
Corticobasal degeneration Frontal Lobe L1 Negative PHF1 
FLTD with TDP 
proteinopathy 
Frontal Lobe L1 Negative pTDP 




SI Figure 4B.  Specificity of Fluselenamyl (5) for Aβ plaques in Alzheimer’s disease compared with 
biomarkers of other neurodegenerative diseases: Columns: 1-5 (left-Right).  Human brain areas (used for 
obtaining tissue sections; 2rd Column); results for Fluselenamyl (5) (4th Column), and antibodies (positive 


















SI Figure 5.  Radio-HPLC data of purified [18F]-9, an Aβ-targeted probe, spiked with an unlabeled 
counterpart (5) for characterization of the radiotracer. 
  










SI Figure 6.  Stability in Human Serum. Radio-HPLC of 18F-9 (red) spiked with cold (blue), and following 
incubation (green, pink, and purple) with human serum.  Peaks are offset for clarity. Note stability of the 












SI, Table 1.  Biodistribution Data (%ID/g) of [18F]-9 in FVB mice (n = 3). 
 
Organ (% ID/g)               2                    60                                        120 min  
Blood                            4.79 ± 0.33                            2.27 ± 0.06                       2.16 ± 0.03 
Brain                             8.86± 0.32                             1.80 ± 0.02                       1.66 ± 0.01 
Bone                             1.15 ± 0.15                             3.88 ± 1.48                       6.08 ± 0.85 
Liver                             35.44 ± 2.52                           8.64 ± 0.15                       8.13 ± 0.12 
Kidney                          14.93± 0.85                            2.52 ± 0.06                      2.12 ± 0.09 
Heart                             8.56± 0.78                             2.15 ± 0.02                       1.92 ± 0.05 
Lung                             10.07± 0.74                            2.23 ± 0.11                       1.98 ± 0.05 
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  Table 2.  Crystal data and structure refinement parameters for 5. 
Identification code  v18213t5/rt/X8  
Empirical formula  C19 H20 F N5 O Se 
Formula weight  432.36 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 4.1693(5) Å α= 90°. 
 b = 25.146(3) Å β= 93.403(7)°. 
 c = 18.0584(18) Å γ = 90°. 
Volume 1889.9(4) Å3 
Z 4 
Density (calculated) 1.520 Mg/m3 
Absorption coefficient 2.016 mm-1 
F(000) 880 
Crystal size 0.594 x 0.076 x 0.054 mm3 
Theta range for data collection 1.975 to 24.997°. 
Index ranges -4≤h≤4, 0≤k≤29, 0≤l≤21 
Reflections collected 3339 
Independent reflections 3339 [R(int) = 0.0405] 
Completeness to theta = 25.000° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.745160 and 0.590024 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3339 / 388 / 249 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0634, wR2 = 0.1465 
R indices (all data) R1 = 0.1156, wR2 = 0.1710 
Extinction coefficient n/a 
Largest diff. peak and hole 0.582 and -0.396 e.Å-3 
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 Table 3.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 5.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Se(1) 2849(2) 746(1) 750(1) 55(1) 
F(1) 10316(14) -1529(2) 4026(3) 86(2) 
O(1) 9116(14) -878(2) 2768(3) 58(2) 
N(1) 6337(16) 934(2) 2050(3) 47(2) 
N(2) 9956(16) 2920(2) 3300(3) 52(2) 
N(3) 10726(16) 1992(2) 3552(3) 53(2) 
N(4) 13016(16) 2640(2) 4328(3) 57(2) 
C(1) 4632(19) 187(3) 1318(4) 44(2) 
C(2) 4470(20) -358(3) 1193(4) 52(2) 
C(3) 6009(18) -693(3) 1683(4) 49(2) 
C(4) 7709(19) -498(3) 2319(4) 46(2) 
C(5) 7881(19) 40(2) 2462(4) 45(2) 
C(6) 6261(18) 386(2) 1948(3) 40(2) 
C(7) 4753(18) 1189(3) 1520(4) 46(2) 
C(8) 4320(20) 1754(3) 1424(4) 59(2) 
C(9) 5427(19) 2179(3) 1817(4) 53(2) 
C(10) 7463(18) 2265(2) 2477(4) 45(2) 
C(11) 8140(20) 2788(3) 2704(4) 52(2) 
C(12) 11257(18) 2515(3) 3706(4) 44(2) 
C(13) 8942(19) 1882(3) 2949(4) 50(2) 
C(14) 13780(20) 3190(3) 4497(4) 70(3) 
C(15) 14350(20) 2234(3) 4820(4) 72(3) 
C(16) 10974(18) -716(3) 3415(4) 55(2) 
C(17) 12570(20) -1189(3) 3773(5) 70(2) 
N(1S') 3130(110) 900(10) 3731(19) 226(15) 
C(1S') 5110(110) 811(10) 4140(30) 226(15) 
C(2S') 6370(110) 382(10) 4571(15) 226(15) 
N(1S) 1760(130) 924(15) 4191(19) 250(20) 
C(1S) 2440(160) 518(15) 4358(19) 250(20) 
C(2S) 2700(130) 128(13) 4910(20) 250(20) 
________________________________________________________________________________ 
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 Table 4.   Bond lengths [Å] and angles [°] for 5. 
_____________________________________________________  
Se(1)-C(1)  1.868(7) 
Se(1)-C(7)  1.917(7) 
F(1)-C(17)  1.370(9) 
O(1)-C(4)  1.364(8) 
O(1)-C(16)  1.423(9) 
N(1)-C(7)  1.299(8) 
N(1)-C(6)  1.389(8) 
N(2)-C(11)  1.322(9) 
N(2)-C(12)  1.349(8) 
N(3)-C(13)  1.310(8) 
N(3)-C(12)  1.361(8) 
N(4)-C(12)  1.342(9) 
N(4)-C(15)  1.444(9) 
N(4)-C(14)  1.447(9) 
C(1)-C(6)  1.383(9) 
C(1)-C(2)  1.389(9) 
C(2)-C(3)  1.358(10) 
C(2)-H(2)  0.9300 
C(3)-C(4)  1.401(10) 
C(3)-H(3)  0.9300 
C(4)-C(5)  1.379(9) 
C(5)-C(6)  1.415(9) 
C(5)-H(5)  0.9300 
C(7)-C(8)  1.441(9) 
C(8)-C(9)  1.348(9) 
C(8)-H(8)  0.9300 
C(9)-C(10)  1.437(10) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.400(9) 
C(10)-C(13)  1.406(9) 
C(11)-H(11)  0.9300 
C(13)-H(13)  0.9300 
C(14)-H(14A)  0.9600 
C(14)-H(14B)  0.9600 
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C(14)-H(14C)  0.9600 
C(15)-H(15A)  0.9600 
C(15)-H(15B)  0.9600 
C(15)-H(15C)  0.9600 
C(16)-C(17)  1.491(10) 
C(16)-H(16A)  0.9700 
C(16)-H(16B)  0.9700 
C(17)-H(17A)  0.9700 
C(17)-H(17B)  0.9700 
N(1S')-C(1S')  1.103(10) 
C(1S')-C(2S')  1.410(10) 
C(2S')-H(2S1)  0.9600 
C(2S')-H(2S2)  0.9600 
C(2S')-H(2S3)  0.9600 
N(1S)-C(1S)  1.098(10) 
C(1S)-C(2S)  1.398(10) 
C(2S)-H(2S4)  0.9600 
C(2S)-H(2S5)  0.9600 






























































































Symmetry transformations used to generate equivalent atoms:  
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 Table 5.   Anisotropic displacement parameters (Å2x 103) for 5.  The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Se(1) 63(1)  56(1) 43(1)  -4(1) -8(1)  -3(1) 
F(1) 86(4)  70(3) 101(4)  36(3) -13(3)  -5(3) 
O(1) 71(4)  40(3) 61(3)  4(2) -4(3)  0(2) 
N(1) 56(4)  38(3) 46(3)  -6(2) -6(3)  1(3) 
N(2) 65(4)  38(3) 53(3)  0(2) -11(3)  3(3) 
N(3) 69(4)  40(3) 50(3)  3(2) -13(3)  -3(3) 
N(4) 69(5)  46(3) 55(3)  -3(2) -17(3)  -6(3) 
C(1) 48(5)  47(3) 38(3)  -4(2) 6(3)  -4(3) 
C(2) 60(5)  52(3) 44(4)  -9(3) 6(4)  -10(3) 
C(3) 59(5)  40(3) 48(3)  -9(3) 7(3)  -10(3) 
C(4) 49(5)  39(3) 52(3)  -1(3) 5(3)  -8(3) 
C(5) 54(5)  38(3) 42(3)  -6(2) -2(3)  -5(3) 
C(6) 47(4)  40(3) 32(3)  -6(2) 4(3)  -7(3) 
C(7) 46(5)  49(3) 43(4)  0(3) -2(3)  2(3) 
C(8) 79(6)  48(3) 48(4)  -2(3) -13(4)  7(3) 
C(9) 69(5)  39(3) 51(4)  1(3) -5(4)  5(3) 
C(10) 55(5)  34(3) 45(3)  4(2) -2(3)  4(3) 
C(11) 60(5)  41(3) 55(4)  3(3) -1(4)  3(3) 
C(12) 48(5)  40(3) 45(3)  0(2) 5(3)  -1(3) 
C(13) 68(5)  38(3) 44(3)  -3(3) -7(3)  5(3) 
C(14) 85(7)  52(4) 73(5)  -11(4) -8(5)  -4(4) 
C(15) 83(7)  64(5) 66(5)  11(4) -18(5)  -3(5) 
C(16) 50(5)  53(4) 61(4)  2(3) 4(3)  -3(4) 
C(17) 66(6)  59(4) 83(5)  12(4) -6(4)  -2(4) 
N(1S') 380(40)  80(10) 210(30)  16(12) -30(20)  43(17) 
C(1S') 380(40)  80(10) 210(30)  16(12) -30(20)  43(17) 
C(2S') 380(40)  80(10) 210(30)  16(12) -30(20)  43(17) 
N(1S) 370(40)  200(30) 170(20)  -130(20) -100(30)  70(30) 
C(1S) 370(40)  200(30) 170(20)  -130(20) -100(30)  70(30) 
C(2S) 370(40)  200(30) 170(20)  -130(20) -100(30)  70(30) 
______________________________________________________________________________ 
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 Table 6.   Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) 
For 5. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 3318 -491 776 62 
H(3) 5934 -1058 1597 59 
H(5) 9022 171 2881 54 
H(8) 3026 1844 1006 71 
H(9) 4680 2497 1609 64 
H(11) 7238 3062 2415 63 
H(13) 8632 1525 2826 60 
H(14A) 15302 3206 4917 106 
H(14B) 11860 3376 4609 106 
H(14C) 14693 3353 4077 106 
H(15A) 13869 1890 4612 108 
H(15B) 13430 2264 5293 108 
H(15C) 16637 2279 4882 108 
H(16A) 9596 -547 3759 66 
H(16B) 12584 -460 3282 66 
H(17A) 13835 -1371 3417 84 
H(17B) 14010 -1074 4184 84 
H(2S1) 4645 196 4789 339 
H(2S2) 7842 513 4956 339 
H(2S3) 7469 143 4258 339 
H(2S4) 3324 -203 4698 381 
H(2S5) 665 86 5126 381 
H(2S6) 4291 234 5289 381 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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 Table 8.  Hydrogen bonds for 5 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(3)-H(3)...N(2)#1 0.93 2.61 3.511(9) 164.5 
 C(13)-H(13)...N(1) 0.93 2.22 3.048(9) 147.6 
 C(15)-H(15A)...N(1S)#2 0.96 2.68 3.63(4) 170.5 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y-1/2,-z+1/2    #2 x+1,y,z       
  















SI Figure 7.    Projection view of 5 with 30% probability ellipsoids and disordered solvent acetonitrile 
omitted. 
  












SI Figure 8.  Projection view of 5 with 30% probability ellipsoids and disordered solvent acetonitrile 
included. 
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NMR Spectral Data 
 
 
1H spectrum of compound 3 
 
13C NMR Spectrum of compound 3 
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13C NMR Spectrum of compound 4 
 
1H spectrum of compound 5
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13C NMR Spectrum of compound 5 
 
 
1H spectrum of compound 6 
 
13C NMR Spectrum of compound 6 








13C NMR Spectrum of compound 7 
 
 





1H spectrum of compound 8 
 
 
13C NMR Spectrum of compound 8 
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